The company says it suffered substantial reputational and operational harm after being placed on a Pentagon blacklist.

Designation of Chinese firms fuels investor unease, with markets bracing for potential Fed tightening and unwinding of AI trade.

The designation could threaten a key revenue stream for the drug contractor and complicate research, manufacturing and supply chains for American pharmaceutical firms.